B15-B19
Conditions
Interventions
Group 1: Participants that take or have taken Tenofovirproxilfumarat/ emtricitabine 245mg/200mg daily or on demand (PrEP)
Sponsors
WIR Zentrum
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Inclusion Criteria 1) PrEP use between 2016 and inclusion into study 2) informed consent 3) sufficient language skills to read and understand questionaire (provided in German, English and Arabic)
Exclusion criteria
Exclusion criteria: Exclusion Criteria 1) not able to understand informed consent or questionnaires 2) pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary Objective -to document hepatitis B, C or D diagnosis or link to therapy in the context of PrEP initiation or re-initiation - to evaluate testing frequency and incidence rates of hepatitis B, C and D -to evaluate the number of initiated treatments of Hepatitis B, C or D after being diagnosed during PrEP work-up or follow-up - to document the HAV and HBV vaccination status (and catch up during PrEP follow-up) - to document reinfections rates of HCV | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary Objectives - to document the number of ex-PrEP users not linked to care any more - to document the number of successful contacts (by post, telefone or mail) of lost ex-PrEP users - to evaluate HIV and hepatitis diagnosis and treatment after end of PrEP care - to compare sociodemographic data and sexual behaviour in PrEP users with and without hepatitis | — |
Countries
Germany
Contacts
Public ContactAnja Potthoff
WIR-Zentrum
Outcome results
None listed